|Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer.|
|Jump to Full Text|
|PMID: 22334787 Owner: NLM Status: MEDLINE|
|BACKGROUND: Realizing the therapeutic benefits of quercetin is mostly hampered by its low water solubility and poor absorption. In light of the advantages of nanovehicles in the delivery of flavanoids, we aimed to deliver quercetin perorally with nanomicelles made from the diblock copolymer, polyethylene glycol (PEG)-derivatized phosphatidylethanolamine (PE).
METHODS: Quercetin-loaded nanomicelles were prepared by using the film casting method, and were evaluated in terms of drug incorporation efficiency, micelle size, interaction with Caco-2 cells, and anticancer activity in the A549 lung cancer cell line and murine xenograft model.
RESULTS: The incorporation efficiency into the nanomicelles was ≥88.9% when the content of quercetin was up to 4% w/w, with sizes of 15.4-18.5 nm and polydispersity indices of <0.250. Solubilization of quercetin by the nanomicelles increased its aqueous concentration by 110-fold. The quercetin nanomicelles were stable when tested in simulated gastric (pH 1.2) and intestinal (pH 7.4) fluids, and were non-toxic to the Caco-2 cells as reflected by reversible reduction in transepithelial electrical resistance and ≤25% lactose dehydrogenase release. The anticancer activity of quercetin could be significantly improved over the free drug through the nanomicellar formulation when tested using the A549 cancer cell line and murine xenograft model. The nanomicellar quercetin formulation was well tolerated by the tumor-bearing animals, with no significant weight loss observed at the end of the 10-week study period.
CONCLUSION: A stable PEG-PE nanomicellar formulation of quercetin was developed with enhanced peroral anticancer activity and no apparent toxicity to the intestinal epithelium.
|Bee-Jen Tan; Yuanjie Liu; Kai-Lun Chang; Bennie K W Lim; Gigi N C Chiu|
Related Documents :
|21841107 - Folic acid and colorectal cancer: unwarranted fears.
22385077 - Cd133 as a target for colon cancer.
22297257 - Curtailing side effects in chemotherapy: a tale of pkcδ in cisplatin treatment.
6622457 - A method for estimating the potential effects of primary and secondary prevention activ...
23761827 - Autologous immune enhancement therapy: a case report of a stage iv colonic cancer.
14657537 - Breaking bad news: a patient's perspective.
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-02-08|
|Title: International journal of nanomedicine Volume: 7 ISSN: 1178-2013 ISO Abbreviation: Int J Nanomedicine Publication Date: 2012|
|Created Date: 2012-02-15 Completed Date: 2012-09-04 Revised Date: 2013-06-26|
Medline Journal Info:
|Nlm Unique ID: 101263847 Medline TA: Int J Nanomedicine Country: New Zealand|
|Languages: eng Pagination: 651-61 Citation Subset: IM|
|Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.|
|APA/MLA Format Download EndNote Download BibTex|
Analysis of Variance
Antineoplastic Agents / administration & dosage*, chemistry
Antioxidants / administration & dosage, chemistry
Cell Line, Tumor
Cell Survival / drug effects
Drug Carriers / administration & dosage, chemistry
Lung Neoplasms / drug therapy*, pathology
Nanoparticles / administration & dosage, chemistry*
Phosphatidylethanolamines / administration & dosage, chemistry
Polyethylene Glycols / administration & dosage, chemistry
Quercetin / administration & dosage*, chemistry*
Xenograft Model Antitumor Assays
|0/Antineoplastic Agents; 0/Antioxidants; 0/Drug Carriers; 0/Micelles; 0/Phosphatidylethanolamines; 0/Polyethylene Glycols; 117-39-5/Quercetin; 133906-05-5/dioleoyl-N-(monomethoxypolyethylene glycol succinyl)phosphatidylethanolamine|
Journal ID (nlm-ta): Int J Nanomedicine
Publisher: Dove Medical Press
© 2012 Tan et al, publisher and licensee Dove Medical Press Ltd.
collection publication date: Year: 2012
Print publication date: Year: 2012
Electronic publication date: Day: 08 Month: 2 Year: 2012
Volume: 7First Page: 651 Last Page: 661
PubMed Id: 22334787
Publisher Id: ijn-7-651
|Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer|
|Bennie KW Lim|
|Gigi NC Chiu|
|Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
|Correspondence: Correspondence: Gigi NC Chiu, Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Tel +65 6516 5536, Fax +65 6779 1554, Email firstname.lastname@example.org
Cancer is a public health problem that affects many countries in the world. Globally, lung cancer is the leading cause of cancer death. In the treatment of advanced lung cancer, chemotherapy remains the mainstay; however, only modest increase in survival has been observed at the cost of significant toxicity to patients.1 It is imperative to search for new therapeutics with improved efficacy and safety profiles. In the anticancer drug discovery and development process, compounds with the highest anticancer activities often have bulky hydrophobic groups within their chemical structures, rendering them water-insoluble.2 Low water solubility not only gives rise to formulation difficulties but also serious therapeutic challenges. Administering the poorly soluble drug candidate intravenously might result in serious complications such as embolism and respiratory system failure due to drug precipitation,3 whereas poor absorption would result from extravascular dosing.4
The family of flavonoid compounds is one such example which has been shown to be promising for the wide applicability in the prevention and therapy of cancer, neurodegenerative, and cardiovascular diseases. Yet, the major hurdle in their clinical usage is poor water solubility, thus affecting their peroral biological activity.5 Among this family of agents, quercetin has been studied extensively for its anticancer activity, whereby it could inhibit a number of signal transduction targets important to cancer cell survival, proliferation, and metastasis.6,7 Quercetin progressed to early-stage clinical trials as an anticancer agent more than a decade ago; nevertheless, its administration required the use of solvents such as dimethylsulfoxide or ethanol.8 Chemical modifications have been attempted to improve quercetin solubility but could result in a loss of drug potency.9 Thus, alternative strategies based on the use of nanotechnologies have been undertaken to improve the water solubility and/or the bioavailability of quercetin so as to improve its biological activity.5 While most of the nanovehicles are designed with compositions sufficiently stable for intravenous administration, which is the most conventional route for cancer chemotherapy, orally active cancer chemotherapeutics have emerged as an attractive treatment modality because of patient preference, convenience in administration, and applicability in outpatient setting.10 A few studies have shown promising peroral antioxidant activity of quercetin when it was delivered by nanoscaled delivery systems,11,12 and recently, a lipid-based, submicron (~400 nm) vesicular complex of quercetin has been developed with improved peroral anticancer activity as compared to a peroral quercetin suspension.13
In light of the advantages of peroral anticancer drug delivery and recent developments in the use of nanovehicles for the delivery of flavonoids,5 we have attempted to deliver quercetin perorally through the use of polyethylene glycol (PEG)-derivatized phosphatidylethanolamine (PE) as the diblock copolymer to form a self-assembled nanomicellar delivery system, and have compared the anticancer activity of this nanomicellar formulation with a peroral suspension of quercetin. The research on PEG-PE nanomicellar systems, pioneered by Torchilin and Alkan-Onyuksel,14–16 has contributed greatly to the intravenous delivery of water-insoluble agents. For instance, improved therapeutic efficacy of the intravenously administered PEG-lipid micelle formulation of paclitaxel has been demonstrated in tumor-bearing mice.15,16 The potential of PEG-lipid nanomicelles for the peroral administration of water-insoluble compounds has yet to be demonstrated in animal models. Here, we have shown that the peroral anticancer activity of quercetin could be significantly increased when delivered in PEG-PE nanomicellar systems in the A549 human lung tumor xenograft model.
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-PEG2000) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [poly(ethyleneglycol)-2000-N′-carboxyfluorescein] (FITC-DSPE-PEG2000) were purchased from Avanti-Polar-Lipids (Alabaster, AL). Cell culture media and supplements were from Gibco (Grand Island, NY). All other chemicals were purchased from Sigma-Aldrich Inc (St Louis, MO). A549, MDA-MB-231, and Caco-2 cell lines were purchased from the American Type Culture Collection (Manassas, VA).
The quercetin nanomicelles were prepared as follows: briefly, DSPE-PEG2000 was dissolved in chloroform and quercetin in ethanol, the two organic solutions were mixed together according to the various weight proportions of drug and PEG-lipid. Subsequently, the organic phase was evaporated off under a stream of nitrogen gas to obtain a dried thin film. The film was further placed under vacuum for at least 3 hours to remove the residual solvent. Hank’s balanced salt solution or phosphate-buffered saline (PBS) was used to hydrate the thin film to form the nanomicelles. For fluorescence-labeled nanomicelles, 1% of FITC-DSPE-PEG2000 was mixed with 99% of DSPE-PEG2000 (by mole) in chloroform, followed by evaporation and hydration as described above. Unincorporated quercetin was removed by centrifugation at 13,000 rpm for 10 minutes followed by filtration through a 0.2-μm filter. The resultant nanomicelle samples were frozen at −86°C for 8 hours (ULT Freezer; Thermo Electron Corporation Forma, Waltham, MA,) and subsequently lyophilized at −50°C to −55°C for 48 hours at 5 Pa (Alpha 2–4 LDplus Freeze Dryer; Christ, Osterode, Germany). No secondary drying was performed. Lyophilized samples were stored at 4°C ± 2°C until further evaluation, and subsequently were reconstituted to original volume using milli-Q water as and when required. Drug concentration was determined by reading absorbance at 376 nm after mixing the micelle samples in ethanol, using a standard curve constructed with quercetin dissolved in ethanol. The size of the nanomicelles was determined by dynamic light scattering (Malvern Zetasizer 3000HS; Malvern, Worcestershire, UK).
The stability of quercetin nanomicelles were evaluated using two different aqueous media. The composition of the simulated gastric fluid (SGF) was as follows: 0.2% w/v NaCl in 0.7% v/v HCl, pH 1.2, and that of the simulated intestinal fluid (SIF) was as follows: 0.05 M potassium dihydrogen phosphate/0.02 M sodium hydroxide, pH 7.0. The nanomicellar quercetin formulation was dialyzed in 1:5000 v/v in the respective simulated fluids for the specified duration. Subsequently, the formulation was analyzed for size and drug content as described above.
Cells were grown in humidified atmosphere of 5% CO2 at 37°C, with media changed every 3–4 days. Caco-2 cells were maintained in Eagle’s minimal essential medium (EMEM) supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine, and 100 units/mL penicillin and 100 μg/mL streptomycin. Stock cultures were grown in T-75 flasks. Upon 80%–90% confluency, cells were spilt using 2.5% trypsin containing 1.0 mM EDTA. All cell culture media and reagents were obtained from Gibco. A549 and MDA-MB-231 cells were maintained in RPMI1640 medium supplemented with 10% FBS, 2 mM L-glutamine, and 100 units/mL penicillin and 100 μg/mL streptomycin. Upon 80%–90% confluency, cells were spilt using 0.25% trypsin.
Caco-2 cells were seeded in 4-well Lab-tek chamber glass slides from Nalgene Nunc Inc (Naperville, IL) at a density of 7.2 × 104 cells/well and cultured for 21 days.
Subsequently, FITC-labeled nanomicelles were added to the cells and incubated for the specified duration at 37°C. After incubation, cells were washed three times with ice-cold PBS before viewing under a Carl Zeiss fluorescence confocal microscope (Oberkochen, Germany) using 40× objective.
The plating densities for A549 cells, MDA-MB-231 cells, and Caco-2 cells were 5.0 × 103 cells/well, 3.0 × 103 cells/well, and 1.33 × 104 cells/well, respectively, in the 96-well plates. A549 and MDA-MB-231 cells were incubated for 24 hours to allow attachment to plate before experimentation, while Caco-2 cells were incubated for 21 days to allow differentiation and tight junction formation. The medium was aspirated and replaced with serum-supplemented medium containing serial dilutions of quercetin in free (dissolved in ethanol) or nanomicellar form.
For MTT viability assay, the cells were treated at 37°C for the specified duration, and at the end, MTT was added to each well after medium removal and PBS rinsing to remove residual drug. Following a 4-hour incubation at 37°C, the well content was aspirated and 150 μL DMSO was added to dissolve formazan crystals. Absorbance at 570 nm was measured with a Tecan SpectraFluorPlus reader (Tecan, Mannedorf, Switzerland). Cell viability was calculated as follows:
where Abstest, Absbackground, Absvehicle represent the absorbance readings from the quercetin-treated wells, the medium-only wells, and the vehicle control wells, respectively.
For LDH release assay, treatment groups, and conditions were similar to those for MTT viability assay, except that the culture medium was collected at the end of treatment for LDH detection using Cytotox-One Homogenous Membrane Integrity Assay Kit (Promega Corporation, Fitchburg, WI) following the manufacturer’s instructions. Fluorescence was measured using the Tecan SpectraFluorPlus plate reader with an excitation wavelength of 560 nm and emission wavelength of 590 nm. Cytotoxicity was calculated as follow:
where Ftest, Ftriton-X and Fbackground represent the fluorescence readings from the test condition (CNM or vehicle alone), triton-X 0.2%, and background.
Cells were seeded at a density of 1.2 × 104 cells/well in collagen- coated filter membrane polycarbonate transwell inserts (12 mm, 1-μm pore size, 0.3 cm2 growth area) obtained from BD Biocoat (Erembodegem, Belgium) and incubated at 37°C for 21 days. On day 21, the baseline TEER values of Caco-2 cells were measured using Millicell ERS-2 Epithelial Volt-Ohm Meter, and inserts that record > 600 Ωcm2 were used for experiments. The chamber was washed twice with Hank’s balanced salt solution before the addition of drug treatment. The cells were treated for 24 hours at 37°C, and TEER values were recorded every 24 hours over the study duration of 96 hours.
The animal study was conducted in the facilities of the British Columbia Cancer Research Center, with methodologies approved by the Institutional Animal Care Committee of the University of British Columbia, Vancouver, BC, Canada. The mice were cared for and used in accordance with the Canadian Council on Animal Care Guidelines. All mice used were between 20–22 g, and were housed in micro-isolator cages and given free access to food and water. Tumors were established in female Rag-2M mice by a single subcutaneous injection of 5 × 106 A549 cells (in 50 μL) in the lower back area. Tumor growth was monitored by caliper measurements along the length and width. Tumor volumes were calculated by the following formula: Tumor volume = 0.5 × (length × width2). When the tumor size reached 50–100 mm3 (3 weeks post-tumor cell inoculation), mice were randomized into three study groups of six animals per group: (1) untreated control, (2) peroral quercetin suspension (vehicle = 25% v/v ethanol in water), and (3) peroral nanomicellar quercetin. The dose of quercetin was 30 mg/kg, following a schedule of three times per week (Monday/Wednesday/Friday) for 3 weeks. Tumor size and body weight of the mice was monitored thrice weekly. Animals whose tumor size reached 1000 mm3, developed ulcerations, or displayed a weight loss of more than 5% were euthanized.
Where appropriate, results are expressed as mean ± SEM of at least three independent experiments. Statistical significance was assessed using one-way ANOVA followed by Fisher’s least significant difference (LSD) test for multiple comparisons. A P value of <0.05 was considered to be statistically significant. All statistical analyses were carried out using SPSS software (v 19.0; IBM, Armonk, NY).
The commonly used PEG-lipid conjugate, DSPE-PEG2000, was combined with quercetin in various weight proportions (1%–5% w/w of quercetin in DSPE-PEG2000). As shown in Table 1, the incorporation efficiencies of quercetin into the DSPE-PEG2000 nanomicelles were found to be 88.9% and above when the content of quercetin was up to 4% w/w. At 5% w/w, the incorporation efficiency was reduced to 79.3%. The size of the drug-loaded nanomicelles ranged from 15.4 to 18.5 nm (Table 1), and the polydispersity indices were <0.250 for all the nanomicellar formulations. The zeta potentials of the empty and drug-loaded nanomicelles were −11.8 ± 0.7 mV and −14.8 ± 0.7 mV, respectively. The highest concentration of nanomicellar quercetin in Hepes-buffered saline that could be achieved without precipitation was 3 mg/mL. This represents a 110-fold increase in the aqueous concentration of quercetin, calculated based on the aqueous solubility of free quercetin of 80 μM.17,18 Furthermore, nanomicellar quercetin could be processed into a powder by freeze-drying, without the need of a cryoprotectant or lyoprotectant. Reconstitution of the freeze-dried, nanomicellar quercetin with water did not result in a change in size or quercetin content (data not shown). Hence, subsequent evaluation of the nanomicellar formulation was based on the reconstituted nanomicellar quercetin.
The cytotoxicity of nanomicellar quercetin was evaluated in the A549 human lung cancer cell line. The highest concentration of quercetin evaluated was 100 μM, as drug precipitation was observed at higher drug concentrations. As shown in Figure 1, the anticancer activity of quercetin could be significantly improved over the free drug through the nanomicellar formulation, as determined by the MTT viability assay. Of note, non-drug loaded DSPE-PEG2000 nanomicelles did not cause significant toxicity to the A549 lung cancer cells up to a concentration of 1 mM, with cell viability of >85%. To ensure that the cytotoxic effect was not cell line specific, the MDA-MB-231 human breast cancer cell line was treated with free and nanomicellar quercetin. As shown in Suppl Data Figure 1, a similar trend could be observed whereby the activity of quercetin could be significantly increased when formulated into the nanomicelles.
Since the nanomicelles are to be administered perorally, stability in the fluids of the gastrointestinal tract has to be demonstrated. The stability of nanomicellar quercetin was evaluated over time in simulated gastric fluid (SGF, 0.2% w/v NaCl in 0.7% v/v HCl, pH 1.2) and simulated intestinal fluid (SIF, 0.05 M potassium dihydrogen phosphate/0.02 M sodium hydroxide, pH 7.0). The quercetin nanomicelles were found to be stable, without significant change in size or drug precipitation (Figure 2). To investigate the amount of quercetin retained in the nanomicelles, the micelle samples were dialyzed against 1:5000 (v/v) SGF or SIF at 37°C using dialysis cassettes. Approximately 70%–75% of incorporated quercetin was retained in the nanomicelles in the respective simulated fluids (Figure 2).
The well-established Caco-2 cell monolayer was employed as the in vitro model for gastrointestinal epithelium, and the cellular accumulation of the PEG-lipid nanomicelles was assessed by confocal microscopy. To facilitate visualization, the nanomicelles were spiked with 1 mol% DSPE-PEG2000-N-carboxyfluorescein. The Caco-2 cells were exposed to the fluorescence-labeled nanomicelles for up to 24 hours at 37°C, and cellular accumulation of the nanomicelles increased over time (Figure 3A). Furthermore, the accumulation of the nanomicelles was independent of P-gp activity and endocytic processes, which was supported by results summarized in Suppl Data Figure 2. Cellular accumulation of the carboxyfluorescein-tagged nanomicelles occurred even in the presence of the P-gp inhibitor cyclosporine A or in the presence of endocytic inhibitors (hyperosmotic sucrose of 0.45 M or Brefeldin A) or a change of incubation temperature from 37°C to 4°C. Collectively, these data suggest that the nanomicelles are likely to accumulate inside Caco-2 cells by passive diffusion.
One possible route to facilitate drug absorption through the intestinal epithelium is by disrupting the tight junctions and thus making paracellular transport of drug molecules possible, which could be reflected by a decrease in the TEER.19 Nevertheless, it is also of equal importance that the disruption of the epithelial tight junctions is only transient, as irreversible disruption could represent potential toxicity to the intestinal epithelium. As such, differentiated Caco-2 cell monolayers grown in transwell inserts were exposed to free or nanomicellar quercetin for 24 hours, and TEER measurements were carried out over a time course of 96 hours. As shown in Figure 3B, Caco-2 cell monolayer treated with free quercetin had small yet statistically significant increase in TEER after 48 hours of exposure that gradually decreased back to control level (t = 0 hours). This observation is in line with the protective effect of quercetin on the intestinal barrier function, which acts by promoting the assembly and expression of tight junction proteins.20 In contrast, significant reduction in TEER was observed in Caco-2 cell monolayer treated with nanomicellar quercetin during the first 48 hours. Of note, the reduction in TEER in the nanomicellar quercetin treatment group could be gradually increased back to control level (t = 0 hours), indicating the reversibility of the treatment.
To further investigate the potential toxicity of the nanomicellar quercetin formulation, release of LDH was determined in differentiated Caco-2 cell monolayer upon 24-hour treatment with free or nanomicellar quercetin (Figure 4). Treatment with free quercetin was non-toxic over the concentration range tested, with ~10% LDH released relative to triton-X control. In contrast, nanomicellar quercetin treatment yielded a small but significant increase in LDH release of ~25% relative to triton-X control. Empty, non-drug loaded nanomicelles were evaluated at concentrations up to 1 mM and were found to be relatively non-toxic to the Caco-2 cell monolayer, with viability of ~80% at 1 mM (Suppl Data, Figure 3).
Based on the in vitro evaluation of the nanomicellar quercetin formulation which provided promising results, the biological activity of the peroral formulation was further investigated in the A549 lung tumor xenograft model. Quercetin was administered to the tumor-bearing mice via oral gavage either in the nanomicellar form or in a 25% v/v ethanol-based suspension, with a dose of 30 mg/kg following a schedule of three times per week (Monday/Wednesday/Friday) for 3 weeks. The results demonstrated that the anti-tumor activity of quercetin was significantly increased when administered as the peroral nanomicelles compared to control and peroral quercetin suspension (Figure 5A). Specifically, tumor growth inhibition at 10-week post-tumor inoculation was 83% for peroral quercetin suspension and 48% for peroral nanomicellar formulation. The two quercetin formulations were well tolerated by the animals, as reflected by minimal changes in the body weight of the mice (Figure 5B). No unusual observations were made upon necropsies of the animals from all three study groups.
Quercetin, a flavanol that is found in certain vegetables, fruits, and tea, has been shown to have a range of biochemical and biological activities that could have the potential to translate to therapeutic benefits. In addition to its antioxidant and anti-inflammatory effects, quercetin as a tyrosine kinase inhibitor8 is able to modulate multiple signaling pathways that would have considerable implications in the therapeutic and prophylactic values for diseases such as cancer. However, realizing the biological benefits of quercetin in the clinical setting is mostly hampered by its low water solubility and poor absorption into the body. For instance, the baseline plasma concentration of quercetin from dietary intake is 50–80 nM,21 and even with supplementation at 1 g/day for 28 days, the plasma concentration is ~1.5 μM,22 which is far below the concentration that is necessary to bring about the intended pharmacological effects of quercetin (such as the concentrations needed for anticancer effect presented in Figure 1). Thus, it is imperative to develop appropriate vehicles for quercetin, and it is the intention of our current study to develop a peroral nanomicellar system that could potentially improve its anticancer activity, which has not been extensively studied.
Since the quercetin-loaded DSPE-PEG2000 nanomicelles are intended for peroral application, the nanomicelles should be able to withstand the harsh environment of the digestive tract such as the drastic changes in pH, and at the same time, be relatively non-toxic to the intestinal epithelium. As demonstrated in Figure 2, the quercetin nanomicelles were relatively stable at pH 1.2 and pH 7, with no significant changes in size and ~30% release of quercetin. These findings are in good agreement with a previous study by Dabholkar et al which reported no significant change in the size of mixed micelles made of DSPE-PEG2000 and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) incubated in acidic (pH 1.2) and neutral (pH 7.4) conditions.23 In terms of toxicity to the intestinal epithelium, although the incorporation of quercetin into the nanomicelles has slightly increased the cytotoxicity, as reflected by the data in Figure 4, this level of cytotoxicity (~25% as determined by LDH release) was comparable to those reported for TPGS and its analogs which are PEG-derivatives well established for their ability to modulate peroral drug absorption. The Caco-2 cytotoxicity of the TPGS analogs was reported to range from 20%–40%, as determined by LDH release.24 Furthermore, quercetin-loaded nanomicelles did not induce irreversible reduction in the TEER of the Caco-2 epithelium (Figure 3B). This finding, together with those in Figure 4 and Suppl Data Figure 3, showed that the quercetin-loaded nanomicelles were relatively non-toxic, which is in line with another study reporting that empty or meso-tetraphenyl porphine loaded DSPE-PEG2000 micelles were minimally toxic to Caco-2 cells.25
The therapeutic benef its of perorally administered quercetin is limited by poor absorption into the body that could be attributed to a number of reasons, including its chemical structure, low water solubility, and extensive metabolism and degradation in the gastrointestinal tract.26 Of interest, quercetin has been shown to protect the intestinal epithelial barrier function by promoting the expression of a number of tight junction proteins and increase TEER of Caco-2 monolayer,27 implying that quercetin may limit its own absorption into the body by reducing paracellular permeability. Our current DSPE-PEG2000-based peroral nanomicellar formulation could increase the anticancer activity of quercetin by two possible mechanisms with supportive data: (1) increase in the aqueous concentration of quercetin (by 110-fold to 3 mg/mL) through solubilization in the nanomicelles, and (2) increase in permeability through modulation of the epithelial tight junctions as reflected by the transient decrease in TEER. At the molecular level, quercetin is able to increase the distribution of tight junction proteins, ZO-2, occludin, and claudin-1, to the actin cytoskeleton fraction, as well as increase the expression of claudin-4 in cytoskeleton fraction and in whole cell.27 From Figure 3B, it can be seen that empty nanomicelles could reduce TEER reversibly, and it is possible that the empty micelles could disrupt the assembly of the tight junction complex through the partition of DSPE-PEG2000 into the cell membrane bilayer.
Nevertheless, other possible mechanisms that could contribute to the increased activity of quercetin by the nanomicellar peroral formulation could not be ruled out. One such mechanism is the potential ability of the nanomicelles to protect quercetin from the enzymatic and degradative action in the intestinal tract. The metabolism of quercetin is complex, involving the formation of multiple metabolites by different pathways.28 Thus, future investigations on the full pharmacokinetic behavior of the nanomicellar formulation with metabolite profiling are necessary to gain insights if the nanomicelles could indeed protect quercetin from enzymatic metabolism in vivo. Currently, we are establishing mass spectroscopy-based analytical method to characterize the metabonomics of quercetin to address the question. Another possible mechanism is the increased mucoadhesion of the nanomicelles to the intestinal mucosa that could be provided by the PEG shell of the nanomicelles.29 Furthermore, it has been suggested that nanovehicles made of lipids could be taken up by lymphoid tissues in the intestinal tract which in turn could circumvent first pass metabolism.13
It is encouraging that the nanomicellar peroral formulation could enhance the anticancer activity of quercetin at a dose of 30 mg/kg. It has been reported that a dose of 3 g/kg, which is 100-fold higher than ours, did not cause any toxic or harmful effect to mice.30 Thus, future studies could titrate our current dose to higher levels, with the dosing frequency adjusted to daily dosing. The dose titration study could be further coupled to the examination of the correlation between tyrosine kinase inhibition and tumor growth inhibition, which could yield interesting pharmacodynamic data on this nanomicellar peroral formulation. Further evaluation could also include the potential of this nanomicellar peroral formulation as a chemotherapeutic and chemopreventive agent in animal models.
MTT viability of free and nanomicellar quercetin in MDA-MB-231 human breast cancer cell line upon 72 hours of exposure. The concentrations of empty micelle were 96 μM and 192 μM for 30 μM and 60 μM nanomicellar quercetin, respectively.
Notes: Data represent mean ± SEM from three independent experiments. *P < 0.05 as compared to free quercetin group.
Click here for additional data file (ijn-7-651s1.png)
Cellular accumulation of FITC-labeled nanomicelles over 24 hours of incubation under various conditions: (A) at 4°C, (B) at 37°C, (C) without cyclosporine A, (D) with cyclosporine A, (E) without 0.45 M sucrose, (F) with 0.45 M sucrose, (G) without brefeldine A, (H) with brefeldine A.
Notes: Representative images from three independent studies are shown.
Click here for additional data file (ijn-7-651s2.png)
MTT viability of (A) empty, non-drug loaded nanomicelles, (B) quercetin-loaded nanomicelles (showing micelle concentrations), and (C) free quercetin in Caco-2 cell monolayer upon 24 h of exposure.
Click here for additional data file (ijn-7-651s3.png)
The authors declare no conflicting interests in connection with this article.
The authors would like to thank Dr Marcel Bally, Dr Dawn Waterhouse, and Ms Hong Yan (Department of Experimental Therapeutics, BC Cancer Research Center, Canada) for providing the facilities and technical support of the animal experiment. The research project is funded by Singapore Economic Development Board Biomedical Sciences Proof-of- Concept Scheme (COY-15-POC/N197-9).
|1.||Clinical Practice Guidelines: Non-small cell lung cancerNational Comprehensive Cancer NetworkYear: 2008 Available from: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed September 19, 2008|
|2.||Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeabilityJ Pharmacol Toxicol MethodsYear: 200044123524911274893|
|3.||Teicher BA,Andrews PA. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval2nd edTotowa, NJHumana PressYear: 2004|
|4.||Lipinski CA,Lombardo F,Dominy BW,Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdv Drug Deliv RevYear: 2001461–332611259830|
|5.||Leonarduzzi G,Testa G,Sottero B,Gamba P,Poli G. Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoidsCurr Med ChemYear: 2010171749519941477|
|6.||Rahman I,Biswas SK,Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenolsBiochem PharmacolYear: 200672111439145216920072|
|7.||Gupta SC,Kim JH,Prasad S,Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticalsCancer Metastasis RevYear: 201029340543420737283|
|8.||Ferry DR,Smith A,Malkhandi J,et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibitionClin Cancer ResYear: 1996246596689816216|
|9.||Yuan ZP,Chen LJ,Fan LY,et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine modelsClin Cancer ResYear: 200612103193319916707620|
|10.||Bromberg L. Polymeric micelles in oral chemotherapyJ Control ReleaseYear: 200812829911218325619|
|11.||Priprem A,Watanatorn J,Sutthiparinyanont S,Phachonpai W,Muchimapura S. Anxiety and cognitive effects of quercetin liposomes in ratsNanomedicineYear: 200841707818249157|
|12.||Ghosh A,Mandal AK,Sarkar S,Panda S,Das N. Nanoencapsulation of quercetin enhances its dietary efficacy in combating arsenic-induced oxidative damage in liver and brain of ratsLife SciYear: 2009843–4758019036345|
|13.||Date AA,Nagarsenker MS,Patere S,et al. Lecithin-based novel cationic nanocarriers (Leciplex) II: improving therapeutic efficacy of quercetin on oral administrationMol PharmYear: 20118371672621480639|
|14.||Torchilin VP. Micellar nanocarriers: pharmaceutical perspectivesPharm ResYear: 2007241116|
|15.||Alkan-Onyuksel H,Ramakrishnan S,Chai HB,Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of taxolPharm ResYear: 19941122062127909371|
|16.||Gao Z,Lukyanov AN,Chakilam AR,Torchilin VP. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killingJ Drug TargetYear: 2003112879212881194|
|17.||Goniotaki M,Hatziantoniou S,Dimas K,Wagner M,Demetzos C. Encapsulation of naturally occurring flavonoids into liposomes: physicochemical properties and biological activity against human cancer cell linesJ Pharm PharmacolYear: 200456101217122415482635|
|18.||van der Woude H,Gliszczynska-Swiglo A,Struijs K,Smeets A,Alink GM,Rietjens IM. Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humansCancer LettYear: 20032001414714550951|
|19.||Schneeberger EE,Lynch RD. The tight junction: a multifunctional complexAm J Physiol Cell PhysiolYear: 20042866C1213122815151915|
|20.||Suzuki T,Hara H. Role of flavonoids in intestinal tight junction regulationJ Nutr BiochemYear: 201122540140821167699|
|21.||Erlund I,Kosonen T,Alfthan G,et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteersEur J Clin PharmacolYear: 200056854555311151743|
|22.||Conquer JA,Maiani G,Azzini E,Raguzzini A,Holub BJ. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjectsJ NutrYear: 199812835935979482769|
|23.||Dabholkar RD,Sawant RM,Mongayt DA,Devarajan PV,Torchilin VP. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)- based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated effluxInt J PharmYear: 20063151–214815716616818|
|24.||Collnot EM,Baldes C,Wempe MF,et al. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayersJ Control ReleaseYear: 20061111–2354016410030|
|25.||Sezgin Z,Yuksel N,Baykara T. Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administrationInt J PharmYear: 20073321–216116717055200|
|26.||Passamonti S,Terdoslavich M,Franca R,et al. Bioavailability of flavonoids: a review of their membrane transport and the function of bilitranslocase in animal and plant organismsCurr Drug MetabYear: 200910436939419519345|
|27.||Suzuki T,Hara H. Quercetin enhances intestinal barrier function through the assembly of zonula [corrected] occludens-2, occludin, and claudin-1 and the expression of claudin-4 in Caco-2 cellsJ NutrYear: 2009139596597419297429|
|28.||Manach C,Williamson G,Morand C,Scalbert A,Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studiesAm J Clin Nutr.Year: 200581Suppl 1230S242S15640486|
|29.||Sahlin JJ,Peppas NA. Enhanced hydrogel adhesion by polymer inter-diffusion: use of linear poly(ethylene glycol) as an adhesion promoterJ Biomater Sci Polym EdYear: 1997864214369151191|
|30.||Ruiz MJ,Fernandez M,Pico Y,et al. Dietary administration of high doses of pterostilbene and quercetin to mice is not toxicJ Agric Food ChemYear: 20095783180318619292443|
Keywords: quercetin, polymeric micelles, PEG-PE, peroral drug delivery, lung cancer.
Previous Document: Analysis of in situ and ex vivo ?V?3 integrin expression during experimental carotid atherogenesis.
Next Document: Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: inve...